• April 06, 2023

  Initiation of a new Phase 3 global clinical study for the Indication of Fuchs endothelial corneal dystrophy
  [Development code: K-321]

• March 22, 2023

  Initiation of a Phase 3 global clinical study for the Indication of Fuchs endothelial corneal dystrophy
  [Development code: K-321]

• December 26, 2022

  Adani & Kowa Strengthen Business Alliance with Multiple Agreements

• August 26, 2022

  Initiation of Phase 3 clinical study in the United States Indication for Fuchs endothelial corneal dystrophy
  [Development code: K-321]

• March 22, 2022

  Kowa, Adani Power & IHI collaborate for Ammonia Co-firing in Thermal Power Plants in India

• January 06, 2021

  Kowa Company, Ltd. has renewed its corporate website.

• August 26, 2020

  K-115 (Ripasudil Hydrochloride Hydrate), a Rho Kinase Inhibitor, has been approved in Thailand

• July 13, 2020

  K-115 (Ripasudil Hydrochloride Hydrate), a Rho Kinase Inhibitor, has been approved in Malaysia

• March 11, 2020

  K-115 (Ripasudil Hydrochloride Hydrate), a Rho Kinase Inhibitor, has been approved in Singapore

• February 19, 2020

  Fixed Combination Eye Drop of Ripasudil Hydrochloride Hydrate, a Rho Kinase Inhibitor, and Brimonidine Tartrate Started Phase 3 Clinical Studies in Japan
  [Developmental code: K-232]

• August 07, 2014

  University of Tokyo's RCAST, Fujitsu, and Kowa
  Successfully Generate a Novel Active Compound Targeting Cancer Using IT-based Drug Discovery Technology